Categories: NewsPharmaceutical

Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2022 financial results prior to market open on Wednesday, August 3, 2022. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.

Participants can access the conference call live via webcast which will be available on the investor page of our website at http://ir.interceptpharma.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. While not required, it is recommended you join 10 minutes prior to the event’s start. A replay of the call will be available on our website shortly following the completion of the call and will be available for one year. 

About Intercept 
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn. 

Contact 
For more information about Intercept, please contact: 

For investors: 
Nareg Sagherian, Executive Director, Global Investor Relations 
investors@interceptpharma.com

For media: 
Karen Preble, Executive Director, Global Corporate Communications 
media@interceptpharma.com 

Staff

Recent Posts

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

Philadelphia, Pennsylvania--(Newsfile Corp. - May 29, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company")…

3 hours ago

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next…

6 hours ago

Care Career, Inc. Acquires Four Leading Healthcare Staffing Firms in Strategic Growth Move

LAS VEGAS, May 29, 2025 /PRNewswire/ -- Care Career, Inc. (www.carecareer.com) today announced it has…

6 hours ago

Medcrypt Expands Platform Capabilities as Demand for Medical Device Cybersecurity Solutions Surges

New Product Launch, Enterprise Momentum, and Industry Partnerships Fuel Medcrypt's Growth in 2025 SAN DIEGO,…

6 hours ago

Outcomes4Me Secures $21M in Funding to Accelerate AI-Driven Innovation and Drive Global Expansion to Transform Cancer Care

BOSTON, May 29, 2025 /PRNewswire/ -- Outcomes4Me Inc., the developer of the leading direct-to-patient, AI-driven…

6 hours ago